<DOC>
	<DOC>NCT01910363</DOC>
	<brief_summary>To test the safety and efficacy of a new generation botulinum toxin preparation A2NTX for treating stroke patients with lower limb spasticity. - we study the degree of spasticity in the ankle and knee joints, and walking speed in 30 patients with stroke before and after injecting 300 units of BOTOX or A2NTX in a blinded manner as for the patient, the physician, and the examiner. - we also assess the safety of A2NTX and compare it to that of BOTOX.</brief_summary>
	<brief_title>Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>patients with lower limb spasticity after stroke duration more than 6 months Modified Ashworth Scale of ankle joint more than 2 patients with previous botulinum toxin injections to lower limbs patients with serious hepatic, renal or cardiac dysfunction patients with respiratory failure patients who cannot understand the instructions</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>poststroke spasticity</keyword>
	<keyword>lower limb</keyword>
	<keyword>botulinum toxin</keyword>
	<keyword>A2</keyword>
</DOC>